Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis
Brief Summary: This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.


Options:
A: Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CP-690,550 5 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP690,550 | Arm Label: CP-690,550 10 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator | Intervention Type: DRUG; Name: CP690,550; Assigned to Arm(s): CP-690,550 5 mg Arm | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg Arm
B: Arm Label: CP-690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg BID
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: JNJ-54781532 150 mg once daily | Arm Label: JNJ-54781532 25 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 25 mg once daily | Arm Label: JNJ-54781532 75 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 75 mg once daily | Arm Label: JNJ-54781532 150 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 150 mg once daily | Arm Label: JNJ-54781532 75 mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 75 mg twice daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-54781532 25 mg once daily; Assigned to Arm(s): JNJ-54781532 25 mg once daily | Intervention Type: DRUG; Name: JNJ-54781532 75 mg once daily; Assigned to Arm(s): JNJ-54781532 75 mg once daily | Intervention Type: DRUG; Name: JNJ-54781532 150 mg once daily; Assigned to Arm(s): JNJ-54781532 150 mg once daily, Placebo | Intervention Type: DRUG; Name: JNJ-54781532 75 mg twice daily; Assigned to Arm(s): JNJ-54781532 75 mg twice daily
D: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2

Answer: D